Compare
Xencor Inc vs Lifecore Biomedical, Inc. vs Gyre Therapeutics, Inc. vs Karyopharm Therapeutics Inc.
| Latest fiscal year | Xencor Inc XNCR | Lifecore Biomedical, Inc. LFCR | Gyre Therapeutics, Inc. GYRE | Karyopharm Therapeutics Inc. KPTI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-05-25 | 2025-12-31 | 2025-12-31 |
| Revenue | $125.58M | $128.87M | $116.59M | $146.07M |
| Revenue growth (YoY) | +13.7% | +0.5% | +10.2% | +0.6% |
| Gross margin | n/a | 31.3% | n/a | n/a |
| Operating margin | -141.4% | -13.4% | 9.9% | -62.1% |
| Net margin | -73.2% | -30.0% | 8.5% | -134.2% |
| Net income | -$91.92M | -$38.72M | $9.88M | -$196.04M |
| EPS (Diluted) | -$1.24 | -$1.27 | $0.02 | -$17.93 |
| Operating cash flow | -$135.12M | -$206.0K | $1.01M | -$75.37M |
| Free cash flow | -$138.27M | -$13.62M | -$180.0K | -$75.37M |
| Cash & equivalents | $54.07M | $8.27M | $37.07M | $60.54M |
| Total assets | $875.50M | $239.34M | $166.13M | $108.42M |
| Total liabilities | $239.91M | $191.91M | $23.85M | $401.34M |
| Shareholders' equity | $635.59M | $1.34M | $106.03M | -$292.93M |
| Return on year-end equity | -14.5% | n/m | 9.3% | n/a |
| Shares outstanding | 71.87M | 37.03M | 91.31M | 18.31M |
Revenue, most recent five fiscal years
| Fiscal year | Xencor Inc | Lifecore Biomedical, Inc. | Gyre Therapeutics, Inc. | Karyopharm Therapeutics Inc. |
|---|---|---|---|---|
| Latest | $125.58M Ended 2025-12-31 | $128.87M Ended 2025-05-25 | $116.59M Ended 2025-12-31 | $146.07M Ended 2025-12-31 |
| 1 year earlier | $110.49M Ended 2024-12-31 | $128.26M Ended 2024-05-26 | $105.76M Ended 2024-12-31 | $145.24M Ended 2024-12-31 |
| 2 years earlier | $174.62M Ended 2023-12-31 | $103.27M Ended 2023-05-28 | $113.45M Ended 2023-12-31 | $146.03M Ended 2023-12-31 |
| 3 years earlier | $164.58M Ended 2022-12-31 | $111.27M Ended 2022-05-29 | $102.29M Ended 2022-12-31 | $157.07M Ended 2022-12-31 |
| 4 years earlier | $275.11M Ended 2021-12-31 | $100.87M Ended 2021-05-30 | $7.34M Ended 2021-12-31 | $209.82M Ended 2021-12-31 |